Smith & Nephew PLC Sponsored ADR Stock News

Global financial markets are in turmoil this morning after the US President announced sweeping tariffs on several countries in a push to lower the nation's trade deficit. Trump's new tariffs are particularly expected to hurt European companies with significant revenue exposure to the United States.

Shares in Smith & Nephew PLC (LSE:SN) fell 2% after UBS downgraded stock in the med-tech firm to 'neutral' from 'buy' on valuation grounds. The price target remains at £12.50.

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew's proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorshi...

The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the forecast period (2025-2033). The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing ...

Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript

Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion.